Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 0.68 |
| ▸ | MKNK2 | Q9HBH9 | 2/20 | 0.68 |
| ▸ | NNMT | P40261 | 3/20 | 0.57 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.45 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.45 |
| ▸ | KLK3 | P07288 | 1/20 | 0.44 |
| ▸ | ERN1 | O75460 | 2/20 | 0.42 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.42 |
| ▸ | CHEK2 | O96017 | 2/20 | 0.41 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.41 |
| ▸ | SYK | P43405 | 1/20 | 0.41 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.41 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.41 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.41 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.41 |
| ▸ | JAK2 | O60674 | 1/20 | 0.41 |
| ▸ | JAK1 | P23458 | 1/20 | 0.41 |
| ▸ | TYK2 | P29597 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3662920 | 0.81 | MKNK1 (0.71) | MKNK1MKNK2NNMTHSD17B1HSD17B2 | |
| SCHEMBL1569731 | 0.76 | PIK3CG (0.52) | MKNK1MKNK2HSD17B1HSD17B2ERN1 | |
| SCHEMBL1570215 | 0.75 | CYP11B2 (0.44) | MKNK1MKNK2NNMTPIK3CASIRT6 | |
| SCHEMBL71905 | 0.74 | NNMT (1.00) | MKNK1MKNK2NNMTSIRT6 | |
| SCHEMBL29975550 | 0.74 | NNMT (1.00) | MKNK1MKNK2NNMTSIRT6 | |
| Hydrochloric Acid SCHEMBL6234386 | 0.73 | NNMT (0.96) | MKNK1MKNK2NNMTKLK3SIRT6 | |
| Hydrochloric Acid SCHEMBL5013391 | 0.73 | NNMT (0.96) | MKNK1MKNK2NNMTKLK3SIRT6 | |
| SCHEMBL29481150 | 0.72 | MKNK1 (0.62) | MKNK1MKNK2NNMTHSD17B1HSD17B2 | |
| SCHEMBL2224203 | 0.72 | CHEK2 (0.77) | MKNK1MKNK2CHEK2MAP4K4KCNH2 | |
| SCHEMBL31174412 | 0.72 | CYP2A6 (0.68) | MKNK1MKNK2NNMTHSD17B1HSD17B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2307385-A1 | 2 -ARYLAMINOQUINAZOLINES FOR TREATING PROLIFERATIVE DISEASES | Novartis AG (CH) | 2011-04-13 | — | — | EP | disclosed |
| US-20100216767-A1 | QUINAZOLINES FOR PDK1 INHIBITION | AIKAWA MINA | 2010-08-26 | — | — | US | disclosed |
| US-20100121052-A1 | Novel compounds for treating proliferative diseases | JAIN RAMA | 2010-05-13 | — | — | US | disclosed |
| WO-2009153313-A1 | 2 -ARYLAMINOQUINAZOLINES FOR TREATING PROLIFERATIVE DISEASES | NOVARTIS AG (CH) | 2009-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216767-A1 | QUINAZOLINES FOR PDK1 INHIBITION | PDK1, PDK2, PDK3 | MKNK1 9/4885MKNK2 11/4885NNMT 1661/4885 |
| US-20100121052-A1 | Novel compounds for treating proliferative diseases | PDK1, PDK2, PDK3 | MKNK1 41/4885MKNK2 55/4885NNMT 2060/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.